Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Epitope mapping of the protease resistant products of RT-QuIC does not allow the discrimination of sCJD subtypes.

Piconi G, Peden AH, Barria MA, Green AJE.

PLoS One. 2019 Jun 17;14(6):e0218509. doi: 10.1371/journal.pone.0218509. eCollection 2019.

2.

Disease Intervention Specialist Education for the Future: An Analysis of Public Health Curricula.

Mase WA, Hansen AR, Smallwood SW, Shah G, Peden AH, Mulherin T, Bender K.

Public Health Rep. 2018 Nov;133(6):738-748. doi: 10.1177/0033354918792014. Epub 2018 Oct 10.

PMID:
30304646
3.

Amyloid-β accumulation in the CNS in human growth hormone recipients in the UK.

Ritchie DL, Adlard P, Peden AH, Lowrie S, Le Grice M, Burns K, Jackson RJ, Yull H, Keogh MJ, Wei W, Chinnery PF, Head MW, Ironside JW.

Acta Neuropathol. 2017 Aug;134(2):221-240. doi: 10.1007/s00401-017-1703-0. Epub 2017 Mar 27.

4.

UK Iatrogenic Creutzfeldt-Jakob disease: investigating human prion transmission across genotypic barriers using human tissue-based and molecular approaches.

Ritchie DL, Barria MA, Peden AH, Yull HM, Kirkpatrick J, Adlard P, Ironside JW, Head MW.

Acta Neuropathol. 2017 Apr;133(4):579-595. doi: 10.1007/s00401-016-1638-x. Epub 2016 Nov 3.

5.

Comparison of practice based research network based quality improvement technical assistance and evaluation to other ongoing quality improvement efforts for changes in agency culture.

Livingood WC, Peden AH, Shah GH, Marshall NA, Gonzalez KM, Toal RB, Alexander DS, Wright AR, Woodhouse LD.

BMC Health Serv Res. 2015 Jul 31;15:300. doi: 10.1186/s12913-015-0956-3.

6.

Variably protease-sensitive prionopathy, a unique prion variant with inefficient transmission properties.

Diack AB, Ritchie DL, Peden AH, Brown D, Boyle A, Morabito L, Maclennan D, Burgoyne P, Jansen C, Knight RS, Piccardo P, Ironside JW, Manson JC.

Emerg Infect Dis. 2014 Dec;20(12):1969-79. doi: 10.3201/eid2012.140214.

7.

The prion protein protease sensitivity, stability and seeding activity in variably protease sensitive prionopathy brain tissue suggests molecular overlaps with sporadic Creutzfeldt-Jakob disease.

Peden AH, Sarode DP, Mulholland CR, Barria MA, Ritchie DL, Ironside JW, Head MW.

Acta Neuropathol Commun. 2014 Oct 21;2:152. doi: 10.1186/s40478-014-0152-4.

8.

Molecular pathology in neurodegenerative diseases.

Peden AH, Ironside JW.

Curr Drug Targets. 2012 Nov;13(12):1548-59. Review.

PMID:
22974397
9.

Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease.

McGuire LI, Peden AH, Orrú CD, Wilham JM, Appleford NE, Mallinson G, Andrews M, Head MW, Caughey B, Will RG, Knight RS, Green AJ.

Ann Neurol. 2012 Aug;72(2):278-85. doi: 10.1002/ana.23589.

10.

Sensitive and specific detection of sporadic Creutzfeldt-Jakob disease brain prion protein using real-time quaking-induced conversion.

Peden AH, McGuire LI, Appleford NE, Mallinson G, Wilham JM, Orrú CD, Caughey B, Ironside JW, Knight RS, Will RG, Green AJ, Head MW.

J Gen Virol. 2012 Feb;93(Pt 2):438-49. doi: 10.1099/vir.0.033365-0. Epub 2011 Oct 26.

11.

Distinct stability states of disease-associated human prion protein identified by conformation-dependent immunoassay.

Choi YP, Peden AH, Gröner A, Ironside JW, Head MW.

J Virol. 2010 Nov;84(22):12030-8. doi: 10.1128/JVI.01057-10. Epub 2010 Sep 15.

12.

The application of in vitro cell-free conversion systems to human prion diseases.

Jones M, Peden AH, Head MW, Ironside JW.

Acta Neuropathol. 2011 Jan;121(1):135-43. doi: 10.1007/s00401-010-0708-8. Epub 2010 Jun 10. Review.

PMID:
20535485
13.

Human platelets as a substrate source for the in vitro amplification of the abnormal prion protein (PrP) associated with variant Creutzfeldt-Jakob disease.

Jones M, Peden AH, Yull H, Wight D, Bishop MT, Prowse CV, Turner ML, Ironside JW, MacGregor IR, Head MW.

Transfusion. 2009 Feb;49(2):376-84. doi: 10.1111/j.1537-2995.2008.01954.x. Epub 2008 Oct 29.

PMID:
18980616
14.

Effects of human PrPSc type and PRNP genotype in an in-vitro conversion assay.

Jones M, Peden AH, Wight D, Prowse C, Macgregor I, Manson J, Turner M, Ironside JW, Head MW.

Neuroreport. 2008 Dec 3;19(18):1783-6. doi: 10.1097/WNR.0b013e328318edfa.

PMID:
18955905
15.

Advances in the development of a screening test for variant Creutzfeldt-Jakob disease.

Peden AH, Head MW, Jones M, Macgregor I, Turner M, Ironside J.

Expert Opin Med Diagn. 2008 Feb;2(2):207-19. doi: 10.1517/17530059.2.2.207.

PMID:
23485140
16.

Disease-associated prion protein is not detectable in human systemic amyloid deposits.

Tennent GA, Head MW, Bishop M, Hawkins PN, Will RG, Knight R, Peden AH, McCardle LM, Ironside JW, Pepys MB.

J Pathol. 2007 Dec;213(4):376-83.

PMID:
17955450
17.

In vitro amplification and detection of variant Creutzfeldt-Jakob disease PrPSc.

Jones M, Peden AH, Prowse CV, Gröner A, Manson JC, Turner ML, Ironside JW, MacGregor IR, Head MW.

J Pathol. 2007 Sep;213(1):21-6.

PMID:
17614097
18.

Abnormal prion protein in the pituitary in sporadic and variant Creutzfeldt-Jakob disease.

Peden AH, Ritchie DL, Uddin HP, Dean AF, Schiller KA, Head MW, Ironside JW.

J Gen Virol. 2007 Mar;88(Pt 3):1068-72.

PMID:
17325383
19.
20.

Risks of transmission of variant Creutzfeldt-Jakob disease by blood transfusion.

Peden AH, Ritchie DL, Ironside JW.

Folia Neuropathol. 2005;43(4):271-8. Review.

21.

Abnormal prion protein in the retina of the most commonly occurring subtype of sporadic Creutzfeldt-Jakob disease.

Head MW, Peden AH, Yull HM, Ritchie DL, Bonshek RE, Tullo AB, Ironside JW.

Br J Ophthalmol. 2005 Sep;89(9):1131-3.

22.

BCR kinase phosphorylates 14-3-3 Tau on residue 233.

Clokie SJ, Cheung KY, Mackie S, Marquez R, Peden AH, Aitken A.

FEBS J. 2005 Aug;272(15):3767-76.

23.

Review: pathology of variant Creutzfeldt-Jakob disease.

Peden AH, Ironside JW.

Folia Neuropathol. 2004;42 Suppl A:85-91. Review.

PMID:
15449463
24.

Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.

Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW.

Lancet. 2004 Aug 7-13;364(9433):527-9.

PMID:
15302196
25.

Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2.

Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, Baillie GS, Houslay MD.

J Biol Chem. 2003 Aug 29;278(35):33351-63. Epub 2003 Jun 16.

26.

TAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid.

Baillie GS, Huston E, Scotland G, Hodgkin M, Gall I, Peden AH, MacKenzie C, Houslay ES, Currie R, Pettitt TR, Walmsley AR, Wakelam MJ, Warwicker J, Houslay MD.

J Biol Chem. 2002 Aug 2;277(31):28298-309. Epub 2002 May 6.

27.

An overview of coding and its relationship to standardized clinical terminology.

Peden AH.

Top Health Inf Manage. 2000 Nov;21(2):1-9. Review.

PMID:
11143274
28.
29.

Intracellular compartmentalization of PDE4 cyclic AMP-specific phosphodiesterases.

Scotland G, Beard M, Erdogan S, Huston E, McCallum F, MacKenzie SJ, Peden AH, Pooley L, Rena NG, Ross AH, Yarwood SJ, Houslay MD.

Methods. 1998 Jan;14(1):65-79.

PMID:
9500859
30.

Current practices in discharge analysis and record assembly.

Peden AH.

J Am Med Rec Assoc. 1990 Oct;61(10):37-44.

PMID:
10107357
31.

Supplemental Content

Loading ...
Support Center